BioSpace News Archive

The Pharmacy Technician Certification Board is pleased to announce a collaboration with the American Pharmacists Association to provide pharmacy technician credentialing in immunization delivery to those completing the APhA/Washington State University Pharmacy-Based Immunization Administration by Pharmacy Technicians Program.

The PA Clinical Network and Geisinger Health Plan (GHP) announced today a new, value-based contract to achieve better health outcomes and lower costs for GHP members.

The Christopher & Dana Reeve Foundation National Paralysis Resource Center announced that it is funding fifty-two Direct Effect Quality of Life Grants, totaling $918,046.

ABEC acknowledged as a model for exemplary worksite safety and health programs among industry peers

Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (“ADHD”), today announced the publication of an original paper in the Journal of Clinical Psychopharmacology that describes a model that may facilitate dosage optimization of JORNAY PM® (methylphenidate

Therap is happy to announce the addition of the Secure Communications (SComm) on its mobile applications platform for iOS and Android devices

Biocare Medical , a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, announces a collaborative partnership with Bethyl Laboratories to develop targeted antibodies for cancer research and oncology diagnostics. Bethyl Laboratories has 45 years of experience in

North Sur Resources Inc. and Mindset Pharma Inc. are pleased to announce that they have signed a binding letter of intent to combine their corporate entities.

OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the benefits of its OmniSeq Advance® comprehensive genomic and immune profiling assay to detect the presence of rare alterations in the RET gene in the tumors of some patients with non-small cell lung cancer (NSCLC) and thyroid cancer

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases